Marina Biotech, Cambridge Biolabs LLC deal

Cambridge Biolabs returned rights to use Marina's transKingdom RNAi (tkRNAi) delivery technology for agriculture and veterinary uses. Cambridge Biolabs will retain exclusive rights to use the technology for undisclosed veterinary applications, for which Marina is eligible for milestones and royalties. Cambridge Biolabs, formerly ViThera LLC, had rights to the technology under a March 2010 deal with Cequent Pharmaceuticals Inc., which Marina acquired in July 2010. Terms were not disclosed. ...